Biologics license application for narsoplimab in hsct-tma accepted for priority review by u.s. fda

Seattle--(business wire)--omeros corporation (nasdaq: omer) announced today that the biologics license application (bla) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) has been accepted for filing by the u.s. food and drug administration (fda). the bla has been granted priority review with an fda action date of july 17, 2021 under the prescription drug user fee act (pdufa). fda also indicated in its filing letter that the
OMER Ratings Summary
OMER Quant Ranking